Country: Malta
Language: English
Source: Medicines Authority
BUDESONIDE
Italchimici S.p.A. Via Pontina n.5, km 29 00071 Pomezia, Rome, Italy
R03BA02
BUDESONIDE 40 mg
PRESSURISED INHALATION, SUSPENSION
BUDESONIDE 40 mg
POM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Withdrawn
2006-08-03
AIRCORT 200MCG/PUFF PRESSURISED SUSPENSION FOR INHALATION INSERT LEAFLET ________________________________________________________________________________ THERAPEUTICAL CLASSIFICATION Anti-asthmatic corticosteroid for inhalation. INDICATIONS Bronchial asthma. CONTRA-INDICATIONS - Hypersensitivity to the active ingredient or to any of the components. - Lung tuberculosis and other bacterial , viral or fungal airways infections. PRECAUTIONS FOR USE Aircort is recommended for the treatment of bronchial asthma and must be used regularly and for the length of time indicated by your physician . In the case of gastric ulcer, the patient must be closely monitored during the entire therapeutic period. Aircort cannot be used in case of acute asthma attacks, in which case it is necessary to administer a bronchodilator by inhalation with rapid onset of action. The physician must carefully evaluate the cases where patients are not benefiting from short acting bronchodilators or who tend to increase their daily intake of bronchodilators well above the average recommended dosage. In these cases the physician must consider the necessity of increasing their therapy with anti-inflammatory medications, e.g. by increasing inhaled budesonide dosage or starting an oral steroid therapy. Particular care is needed in transferring patients from oral steroids to the inhalation therapy because the risk of suprarenal damage may persist for a long time. This risk may pertain also to those patients who underwent rescue therapy with high systemic corticosteroid doses or prolonged high i Read the complete document
Page 1 of 6 1- NAME OF THE MEDICINAL PRODUCT AIRCORT 200 micrograms/puff, Pressurised Suspension for Inhalation 2- QUALITATIVE AND QUANTITATIVE COMPOSITION 1 pressurised can contains: budesonide 40 mg For excipients , see 6.1 3- PHARMACEUTICAL FORM Pressurised suspension for inhalation. 4- CLINICAL PARTICULARS 4.1 – THERAPEUTIC INDICATIONS Bronchial asthma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Aircort dosage must be adjusted to the individual patient’s need in relation to the severity of his asthma and treatment phase. _Adults_: in the case of severe asthma at the start of the inhaled steroid therapy or during reduction- substitution of the oral corticosteroid therapy, the indicated dose is 200 micrograms (one puff) 2-4 times daily. In patients whose maintenance dose must be individually determined and which should be the minimum dose that keeps asthma symptoms under control: normally one inhalation of 200 micrograms (one puff) daily is sufficient. _Children from 5 years above_: generally 200 micrograms (one puff) daily. If needed, the dosage may be doubled. In the case of asthma exacerbations the dosage of Aircort may be increased according to the physician’s judgement. _Time for effectiveness _ Amelioration of asthma symptoms may be observed within 24 hours from the start of Aircort administration. However, full benefit is usually achieved after 1-2 weeks or more of treatment. _Patients not treated with steroids_ Therapeutic benefit is usually achieved within 10 days of treatment with Aircort. However, some patients may have an excess of mucous secretion in the bronchi, Read the complete document